Autologous and Allogeneic Bone Marrow Transplantation for Low Grade Lymphoma
OBJECTIVES: I. Examine the potential role of high dose etoposide, cyclophosphamide, total
body irradiation and bone marrow transplantation for patients at high risk for disease
progression. II. Determine the value of monitoring the quality of remission by PCR
assessment of BCl-2. III. Evaluate the efficacy of alpha interferon for patients with
evidence of residual or recurrent lymphoma. IV. Evaluate the efficacy of bone marrow purging
by PCR assessment of BCl-2.
OUTLINE: Patients receive a brief 2-3 cycles of intensive chemotherapy to achieve minimum
disease state. Etoposide is administered intravenously on day -8. Cyclophosphamide is
infused intravenously over 2 hours daily on day -7 and -6. Patients receive mesna beginning
1 hour after initiation of the cyclophosphamide treatment. Total body irradiation is
received on days -4, -3, -2 , and -1. On day 0 allogeneic or autologous bone marrow is
infused intravenously. Patients with residual or recurrent lymphoma receive interferon alpha
daily.
PROJECTED ACCRUAL: 35 allogeneic and 40 autologous patients are expected to be enrolled.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Patients with Response
2 Years
No
Richard E. Champlin, MD
Study Chair
M.D. Anderson Cancer Center
United States: Federal Government
DM94-009
NCT00002829
February 1994
April 2002
Name | Location |
---|---|
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |